S&P 500   4,606.12 (+0.04%)
DOW   36,307.60 (+0.16%)
QQQ   393.41 (+0.32%)
AAPL   192.64 (-1.57%)
MSFT   368.36 (-1.57%)
META   323.63 (-2.74%)
GOOGL   132.47 (-1.87%)
AMZN   144.69 (-1.85%)
TSLA   241.54 (-0.94%)
NVDA   467.00 (-1.70%)
NIO   7.46 (+1.08%)
BABA   70.99 (-1.59%)
AMD   132.33 (+2.65%)
T   16.66 (-1.54%)
F   11.05 (+0.36%)
MU   77.90 (+3.92%)
CGC   0.77 (-4.13%)
GE   120.03 (-0.46%)
DIS   92.46 (-0.39%)
AMC   6.76 (-2.45%)
PFE   28.54 (-0.83%)
PYPL   59.10 (+0.27%)
XOM   98.94 (-0.61%)
S&P 500   4,606.12 (+0.04%)
DOW   36,307.60 (+0.16%)
QQQ   393.41 (+0.32%)
AAPL   192.64 (-1.57%)
MSFT   368.36 (-1.57%)
META   323.63 (-2.74%)
GOOGL   132.47 (-1.87%)
AMZN   144.69 (-1.85%)
TSLA   241.54 (-0.94%)
NVDA   467.00 (-1.70%)
NIO   7.46 (+1.08%)
BABA   70.99 (-1.59%)
AMD   132.33 (+2.65%)
T   16.66 (-1.54%)
F   11.05 (+0.36%)
MU   77.90 (+3.92%)
CGC   0.77 (-4.13%)
GE   120.03 (-0.46%)
DIS   92.46 (-0.39%)
AMC   6.76 (-2.45%)
PFE   28.54 (-0.83%)
PYPL   59.10 (+0.27%)
XOM   98.94 (-0.61%)
S&P 500   4,606.12 (+0.04%)
DOW   36,307.60 (+0.16%)
QQQ   393.41 (+0.32%)
AAPL   192.64 (-1.57%)
MSFT   368.36 (-1.57%)
META   323.63 (-2.74%)
GOOGL   132.47 (-1.87%)
AMZN   144.69 (-1.85%)
TSLA   241.54 (-0.94%)
NVDA   467.00 (-1.70%)
NIO   7.46 (+1.08%)
BABA   70.99 (-1.59%)
AMD   132.33 (+2.65%)
T   16.66 (-1.54%)
F   11.05 (+0.36%)
MU   77.90 (+3.92%)
CGC   0.77 (-4.13%)
GE   120.03 (-0.46%)
DIS   92.46 (-0.39%)
AMC   6.76 (-2.45%)
PFE   28.54 (-0.83%)
PYPL   59.10 (+0.27%)
XOM   98.94 (-0.61%)
S&P 500   4,606.12 (+0.04%)
DOW   36,307.60 (+0.16%)
QQQ   393.41 (+0.32%)
AAPL   192.64 (-1.57%)
MSFT   368.36 (-1.57%)
META   323.63 (-2.74%)
GOOGL   132.47 (-1.87%)
AMZN   144.69 (-1.85%)
TSLA   241.54 (-0.94%)
NVDA   467.00 (-1.70%)
NIO   7.46 (+1.08%)
BABA   70.99 (-1.59%)
AMD   132.33 (+2.65%)
T   16.66 (-1.54%)
F   11.05 (+0.36%)
MU   77.90 (+3.92%)
CGC   0.77 (-4.13%)
GE   120.03 (-0.46%)
DIS   92.46 (-0.39%)
AMC   6.76 (-2.45%)
PFE   28.54 (-0.83%)
PYPL   59.10 (+0.27%)
XOM   98.94 (-0.61%)
Top-Rated StocksTop-Rated

4D Molecular Therapeutics (FDMT) Stock Price, News & Analysis

$14.34
-0.60 (-4.02%)
(As of 10:04 AM ET)
Compare
Today's Range
$14.05
▼
$14.83
50-Day Range
$9.76
▼
$14.94
52-Week Range
$9.44
▼
$26.49
Volume
34,147 shs
Average Volume
406,116 shs
Market Capitalization
$613.09 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$30.50
Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media

4D Molecular Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.88 Rating Score
Upside/​Downside
112.7% Upside
$30.50 Price Target
Short Interest
Bearish
8.82% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($2.54) to ($3.06) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.54 out of 5 stars

Medical Sector

846th out of 942 stocks

Biological Products, Except Diagnostic Industry

147th out of 157 stocks

See Top Rated MarketRank™ Stocks Here

FDMT stock logo

About 4D Molecular Therapeutics Stock (NASDAQ:FDMT)

4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform. It develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has product candidates that are in clinical trials, such as 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease cardiomyopathy. Its product candidates also include 4D-150 for the treatment of wet age-related macular degeneration and diabetic macular edema; and 4D-710 for the treatment of cystic fibrosis lung disease. In addition, the company has two product candidates that are in preclinical development stage, such as 4D-175 for the treatment of geographic atrophy; and 4D-725 for the treatment of alpha-1 antitrypsin deficiency lung disease. It has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.

FDMT Stock Price History

FDMT Stock News Headlines

December 4, 2023 | finance.yahoo.com
4DMT to Present Interim 24 Week Data from Randomized Phase 2 PRISM Clinical Trial of 4D-150 in High Treatment Need Wet AMD Patients at Angiogenesis, Exudation, and Degeneration 2024 Conference
November 14, 2023 | finance.yahoo.com
Broker Revenue Forecasts For 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Are Surging Higher
December 11, 2023 | Edge On The Street (Ad)
U.S. Military Defense Fails Without Vanadium?
The metal vanadium is needed for numerous military applications, including jet engines, airframes, and ballistic missiles. And although the U.S. Govt. considers vanadium critical to national security, less than 5% of the metal is mined in America. This means we're at the mercy of China and Russia for our supply.
November 12, 2023 | finance.yahoo.com
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
November 10, 2023 | markets.businessinsider.com
4D Molecular Therapeutics Continues Growth: Q3 Financials and Progress in Ophthalmology Trials Reinforce Buy Rating
November 10, 2023 | finanznachrichten.de
4D Molecular Therapeutics, Inc.: 4DMT Reports Third Quarter 2023 Financial Results and Operational Highlights
November 9, 2023 | finance.yahoo.com
4DMT Reports Third Quarter 2023 Financial Results and Operational Highlights
November 1, 2023 | finance.yahoo.com
4DMT Presents Positive Interim Data from Phase 1/2 AEROW Clinical Trial of Aerosolized 4D-710 for Cystic Fibrosis at 2023 NACFC
December 11, 2023 | Autonomix (Ad)
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology
Autonomix is preparing a public listing as they develop technology to potentially detect and treat a range of nervous system disorders with much greater visibility than available today. Now, their management team sees a potentially untapped $100B market opportunity.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
October 30, 2023 | finance.yahoo.com
4DMT Gains Alignment with FDA on Plan to Lift Clinical Hold on Phase 1/2 INGLAXA Clinical Trial for 4D-310 for Fabry Disease Cardiomyopathy
October 26, 2023 | msn.com
Cantor starts 4D Molecular at overweight, says shares don't reflect progress
October 25, 2023 | msn.com
Cantor Fitzgerald Initiates Coverage of 4D Molecular Therapeutics (FDMT) with Overweight Recommendation
October 25, 2023 | finance.yahoo.com
4DMT to Present Interim Data from Aerosolized 4D-710 Phase 1/2 AEROW Clinical Trial for Cystic Fibrosis at 2023 NACFC
October 23, 2023 | finance.yahoo.com
4DMT Receives EMA Priority Medicines (PRIME) Designation for 4D-150 Clinical-Stage Genetic Medicine for Treatment of Wet AMD
September 25, 2023 | msn.com
4D Molecular Therapeutics: Some Failures, A Few Key Successes
September 14, 2023 | finanznachrichten.de
4D Molecular Therapeutics, Inc.: 4DMT Appoints Uneek Mehra as Chief Financial and Business Officer
September 7, 2023 | finance.yahoo.com
4DMT Announces First Patient Enrolled in 4D-150 Phase 2 SPECTRA Clinical Trial in DME, and Expansion of 4D-150 Phase 2 Stage in PRISM Clinical Trial in Wet AMD
September 7, 2023 | finance.yahoo.com
4DMT to Participate in Upcoming Investor Conferences
August 9, 2023 | finance.yahoo.com
4D Molecular Therapeutics Reports Second Quarter 2023 Financial Results and Operational Highlights
August 9, 2023 | finance.yahoo.com
Despite currently being unprofitable, 4D Molecular Therapeutics (NASDAQ:FDMT) has delivered a 59% return to shareholders over 1 year
July 31, 2023 | markets.businessinsider.com
What 6 Analyst Ratings Have To Say About 4D Molecular Therapeutics
July 31, 2023 | markets.businessinsider.com
H.C. Wainwright Sticks to Its Buy Rating for 4D Molecular Therapeutics (FDMT)
July 29, 2023 | finance.yahoo.com
4DMT Presents Additional Positive Interim Data from Intravitreal 4D-150 Phase 1/2 PRISM Clinical Trial in Patients with Wet AMD at ASRS 2023
July 17, 2023 | finance.yahoo.com
4DMT Completes Enrollment of Phase 2 PRISM Clinical Trial for Intravitreal 4D-150 in Patients with Wet AMD and Reports Interim Safety and Tolerability Data
July 14, 2023 | markets.businessinsider.com
SVB Securities Keeps Their Hold Rating on 4D Molecular Therapeutics (FDMT)
July 10, 2023 | seekingalpha.com
4D Molecular Therapeutics: Pioneering Gene Therapies And An Impressive Fiscal Performance
June 9, 2023 | msn.com
B of A Securities Maintains 4D Molecular Therapeutics (FDMT) Buy Recommendation
See More Headlines
Receive FDMT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for 4D Molecular Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/09/2023
Today
12/11/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
3/20/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:FDMT
CUSIP
N/A
CIK
1650648
Web
www.4dmoleculartherapeutics.com
Phone
510-505-2680
Fax
N/A
Employees
144
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$30.50
High Stock Price Target
$50.00
Low Stock Price Target
$13.00
Potential Upside/Downside
+104.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.88
Research Coverage
8 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($2.73)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-107,490,000.00
Net Margins
-436.30%
Pretax Margin
-436.30%
Return on Equity
-34.73%
Return on Assets
-31.45%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
18.07
Quick Ratio
18.07

Sales & Book Value

Annual Sales
$21.99 million
Price / Sales
29.05
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$7.14 per share
Price / Book
2.09

Miscellaneous

Outstanding Shares
42,754,000
Free Float
38,179,000
Market Cap
$638.74 million
Optionable
Not Optionable
Beta
2.45
The 10 Best AI Stocks to Own in 2024 Cover
The 10 Best AI Stocks to Own in 2024

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Key Executives

  • Dr. John F. Milligan Ph.D. (Age 62)
    Executive Chairman
    Comp: $150k
  • Dr. David H. Kirn M.D. (Age 61)
    Co-Founder, CEO & Director
    Comp: $920.97k
  • Dr. Fariborz Kamal Ph.D. (Age 60)
    President & COO
    Comp: $678.4k
  • Ms. Theresa Janke (Age 48)
    Co-Founder & Chief of Staff
    Comp: $652.32k
  • Mr. Uneek Mehra (Age 51)
    Chief Financial & Business Officer
  • Mike Zanoni
    VP of Investor Relations
  • Dr. Scott P. Bizily J.D. (Age 51)
    Ph.D., Chief Legal & Human Resources Officer and Corporate Secretary
  • Dr. Robert Y. Kim M.B.A. (Age 62)
    M.D., Chief Medical Officer
  • Dr. An Song Ph.D.
    Chief Development Officer
  • Ms. Karen S. Carothers (Age 72)
    Controller

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions














FDMT Stock Analysis - Frequently Asked Questions

Should I buy or sell 4D Molecular Therapeutics stock right now?

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for 4D Molecular Therapeutics in the last twelve months. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" FDMT shares.
View FDMT analyst ratings or view top-rated stocks.

What is 4D Molecular Therapeutics' stock price target for 2024?

8 brokers have issued 1 year price objectives for 4D Molecular Therapeutics' shares. Their FDMT share price targets range from $13.00 to $50.00. On average, they expect the company's share price to reach $30.50 in the next twelve months. This suggests a possible upside of 112.7% from the stock's current price.
View analysts price targets for FDMT or view top-rated stocks among Wall Street analysts.

How have FDMT shares performed in 2023?

4D Molecular Therapeutics' stock was trading at $22.21 at the beginning of the year. Since then, FDMT stock has decreased by 35.4% and is now trading at $14.34.
View the best growth stocks for 2023 here.

Are investors shorting 4D Molecular Therapeutics?

4D Molecular Therapeutics saw a increase in short interest in November. As of November 15th, there was short interest totaling 3,770,000 shares, an increase of 7.4% from the October 31st total of 3,510,000 shares. Based on an average trading volume of 337,800 shares, the days-to-cover ratio is presently 11.2 days.
View 4D Molecular Therapeutics' Short Interest.

When is 4D Molecular Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 20th 2024.
View our FDMT earnings forecast.

How were 4D Molecular Therapeutics' earnings last quarter?

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) announced its quarterly earnings data on Thursday, November, 9th. The company reported ($0.24) earnings per share for the quarter, beating the consensus estimate of ($0.67) by $0.43. The firm had revenue of $20.20 million for the quarter, compared to analyst estimates of $6.41 million. 4D Molecular Therapeutics had a negative net margin of 436.30% and a negative trailing twelve-month return on equity of 34.73%.

What ETFs hold 4D Molecular Therapeutics' stock?

ETFs with the largest weight of 4D Molecular Therapeutics (NASDAQ:FDMT) stock in their portfolio include Direxion Moonshot Innovators ETF (MOON).Invesco Dorsey Wright Healthcare Momentum ETF (PTH).

When did 4D Molecular Therapeutics IPO?

(FDMT) raised $101 million in an initial public offering (IPO) on Friday, December 11th 2020. The company issued 4,800,000 shares at a price of $20.00-$22.00 per share. Goldman Sachs, Evercore ISI and William Blair served as the underwriters for the IPO and Chardan was co-manager.

Who are 4D Molecular Therapeutics' major shareholders?

4D Molecular Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include RA Capital Management L.P. (9.74%), Morgan Stanley (3.43%), Northern Trust Corp (0.86%), Healthcare of Ontario Pension Plan Trust Fund (0.83%), Charles Schwab Investment Management Inc. (0.61%) and Wellington Management Group LLP (0.40%). Insiders that own company stock include David Kirn, David Schaffer, Global Investors Lp Viking, Jacob Chacko and Scott Bizily.
View institutional ownership trends.

How do I buy shares of 4D Molecular Therapeutics?

Shares of FDMT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:FDMT) was last updated on 12/11/2023 by MarketBeat.com Staff

My Account -